search
Back to results

New Treatment Perspectives in Adolescents With Anorexia Nervosa: the Efficacy of Non-invasive Brain-directed Treatment

Primary Purpose

Anorexia in Adolescence

Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
AN Active tDCS
AN Sham tDCS
Sponsored by
Bambino Gesù Hospital and Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Anorexia in Adolescence focused on measuring tDCS, EEG, TMS, cortisol, eating disorder, neuromodulation

Eligibility Criteria

10 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: diagnosis of AN according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition - DSM-5 (American Psychiatric Association & American Psychiatric Association, 2013); condition of under-weight (BMI <18.5 kg/m2); intelligence quotient higher or equal to 85 (IQ ≥ 85); ability to give informed consent under parents' surveillance and guidance Exclusion Criteria: a personal history of neurological/medical/genetic diseases; a personal history of epilepsy; suicide risk; receiving CNS-active drug, other counseling or psychological therapies during the treatment.

Sites / Locations

  • Bambino Gesù Hospital and Research InstituteRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

AN Active tDCS

AN Sham tDCS

Arm Description

Treatment "as usual" plus experimental treatment

Treatment "as usual" plus placebo treatment

Outcomes

Primary Outcome Measures

The primary end-point of the study is the variance on eating psychopathology at T1, assessed as changes in Eating Disorder Risk score (EDRC) of the Eating Disorder Inventory (EDI-3). Significant changes in Ineffectiveness (IC) of the EDI-3.
EDI-3 comprises 91-item that give a measure of the basic characteristics of the ED through six composite scores [Eating Disorder Risk (EDRC) (range 0-100), Ineffectiveness (IC) (range 0-48), Interpersonal Problems (IPC) (range 0-52), Affective Problems (APC) (range 0-62), Overcontrol (OC) (range 0-52), and General Psychological Maladjustment (GPMC) (range 0-252)]. Higher scores indicates more severe problems.

Secondary Outcome Measures

Significant changes in Ineffectiveness (IC) of the EDI-3.
Evaluation of the change in Ineffectiveness, with maximum possible score of 48, where higher scores indicate higher Ineffectiveness.
Significant changes in Interpersonal Problems (IPC) of the EDI-3.
Evaluation of the change in Interpersonal Problems, with maximum possible score of 52, where higher scores indicate higher Interpersonal Problems.
Significant changes in Affective Problems (APC) of the EDI-3.
Evaluation of the change in Affective Problems, with maximum possible score of 62, where higher scores indicate higher Affective Problems.
Significant changes in Overcontrol (OC) of the EDI-3.
Evaluation of the change in Overcontrol, with maximum possible score of 52, where higher scores indicate higher Overcontrol.
Significant changes in General Psychological Maladjustment (GPMC) of the EDI-3.
Evaluation of the change in General Psychological Maladjustment, with maximum possible score of 252, where higher scores indicate higher General Psychological Maladjustment.
Significant changes in the total scores of AN symptomatology measures as Eating Attitudes Test (EAT-26)
The EAT-26 proposes a cut-off score of 20. Scores of 20 or higher were considered clinically significant.
Significant changes in the total scores of AN symptomatology measures as Body Uneasiness Test (BUT).
The BUT proposes a cut-off score of 1,2. Scores of 1,2 or higher were considered clinically significant.
Significant changes in the total scores of other psychopathological measures as Child Behavior Checklist (CBCL 6-18).
The CBCL 6-18 generates a T-score for each subscale. According to normative data, a T-score above 64 was considered to be significant for the 3 broadband scales, whereas for the syndrome scales, the cut-off for clinical significance was 70.
Significant changes in the total scores of other psychopathological measures as Children's Depression Inventory (CDI).
Raw scores were converted to T-scores. According to normative data, a T-score above 64 was considered clinical significance.
Significant changes in the total scores of other psychopathological measures as Multidimensional Anxiety Scale for Children (MASC).
Raw scores were converted to T-scores. According to normative data, a T-score above 64 was considered clinical significance.
Significant changes in the physiological measures specifically the BMI index
Number of participants with abnormal laboratory blood test results.
Significant changes in the endogenous stress response, measured with Cortisol Awakening Response (CAR).
Significant changes in intra-cortical inhibitory/excitatory motor circuits using paired pulse TMS, measured as short intracortical inhibition and facilitation.
the ratio between MEPs amplitude conditioning stimulus and MEPs amplitude test stimulus alone for each ISI.
Significant changes in sensory-motor integration using paired pulse TMS, measured as SICI/ICF: the ratio between MEPs amplitude (mV) conditioning stimulus (electrical stimulation) and MEP amplitude test stimulus alone for each ISI.
Significant changes in cortical oscillatory patterns (synchronization and desynchronization) in theta, alpha and beta frequencies (Hz) over motor and premotor cortex, using TMS-EEG co-registration.
Significant changes in cortical connectivity using TMS-EEG co-registration combined to report the analysis of the waveform, latency and cortical distribution of TMS-evoked potentials (TEPs) in micronV.
Significant changes in cortical reactivity in terms of TMS-evoked potentials (TEPs) amplitude for time domain (micronV) and frequency bands for spatial domain (Hz), using TMS-EEG co-registration.
Significant changes in Cortical Plasticity evoked by repetitive TMS in terms of different MEP amplitude (mV) recorded at different time-points after repetitive TMS perturbations.

Full Information

First Posted
December 6, 2022
Last Updated
April 5, 2023
Sponsor
Bambino Gesù Hospital and Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT05674266
Brief Title
New Treatment Perspectives in Adolescents With Anorexia Nervosa: the Efficacy of Non-invasive Brain-directed Treatment
Official Title
New Treatment Perspectives in Adolescents With Anorexia Nervosa: the Efficacy of Non-invasive Brain-directed Treatment
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 30, 2020 (Actual)
Primary Completion Date
June 30, 2023 (Anticipated)
Study Completion Date
January 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bambino Gesù Hospital and Research Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The present randomized, double blind, placebo-controlled trial aims at evaluating the efficacy of a tDCS treatment in improving the clinical outcome of adolescents with AN and investigate brain mechanisms acting in AN.
Detailed Description
The investigators hypothesized that excitatory tDCS over the left PFC and inhibitory tDCS over the right PFC (anode left/cathode right) may aid in altering/resetting inter-hemispheric balance in children and adolescents with AN, reducing their control over eating behaviors and improving the AN psychopathology. Furthermore, the investigators will employ TMS-EEG to directly explore the DLPFC activity of children and adolescent with AN, with specific attention to the differences between hemispheres. Moreover, paired pulse TMS and repetitive TMS protocols will be used to investigate the functional mechanisms within the prefrontal cortex of youth patients with AN. Then, the investigators will assess if potential changes of specific biomarkers, such as those related to the endogenous stress response system functioning, will occur after tDCS treatment and will correlate with clinical improvement.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anorexia in Adolescence
Keywords
tDCS, EEG, TMS, cortisol, eating disorder, neuromodulation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
AN Active tDCS
Arm Type
Experimental
Arm Description
Treatment "as usual" plus experimental treatment
Arm Title
AN Sham tDCS
Arm Type
Sham Comparator
Arm Description
Treatment "as usual" plus placebo treatment
Intervention Type
Device
Intervention Name(s)
AN Active tDCS
Other Intervention Name(s)
Brain Stim
Intervention Description
The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week. tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands. The anode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement. Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min.
Intervention Type
Device
Intervention Name(s)
AN Sham tDCS
Other Intervention Name(s)
Brain Stim Sham
Intervention Description
The same electrode placement will be used as in the stimulation conditions (left anodal/right cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
Primary Outcome Measure Information:
Title
The primary end-point of the study is the variance on eating psychopathology at T1, assessed as changes in Eating Disorder Risk score (EDRC) of the Eating Disorder Inventory (EDI-3). Significant changes in Ineffectiveness (IC) of the EDI-3.
Description
EDI-3 comprises 91-item that give a measure of the basic characteristics of the ED through six composite scores [Eating Disorder Risk (EDRC) (range 0-100), Ineffectiveness (IC) (range 0-48), Interpersonal Problems (IPC) (range 0-52), Affective Problems (APC) (range 0-62), Overcontrol (OC) (range 0-52), and General Psychological Maladjustment (GPMC) (range 0-252)]. Higher scores indicates more severe problems.
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Significant changes in Ineffectiveness (IC) of the EDI-3.
Description
Evaluation of the change in Ineffectiveness, with maximum possible score of 48, where higher scores indicate higher Ineffectiveness.
Time Frame
12 months follow up
Title
Significant changes in Interpersonal Problems (IPC) of the EDI-3.
Description
Evaluation of the change in Interpersonal Problems, with maximum possible score of 52, where higher scores indicate higher Interpersonal Problems.
Time Frame
12 months follow up
Title
Significant changes in Affective Problems (APC) of the EDI-3.
Description
Evaluation of the change in Affective Problems, with maximum possible score of 62, where higher scores indicate higher Affective Problems.
Time Frame
12 months follow up
Title
Significant changes in Overcontrol (OC) of the EDI-3.
Description
Evaluation of the change in Overcontrol, with maximum possible score of 52, where higher scores indicate higher Overcontrol.
Time Frame
12 months follow up
Title
Significant changes in General Psychological Maladjustment (GPMC) of the EDI-3.
Description
Evaluation of the change in General Psychological Maladjustment, with maximum possible score of 252, where higher scores indicate higher General Psychological Maladjustment.
Time Frame
12 months follow up
Title
Significant changes in the total scores of AN symptomatology measures as Eating Attitudes Test (EAT-26)
Description
The EAT-26 proposes a cut-off score of 20. Scores of 20 or higher were considered clinically significant.
Time Frame
12 months follow up
Title
Significant changes in the total scores of AN symptomatology measures as Body Uneasiness Test (BUT).
Description
The BUT proposes a cut-off score of 1,2. Scores of 1,2 or higher were considered clinically significant.
Time Frame
12 months follow up
Title
Significant changes in the total scores of other psychopathological measures as Child Behavior Checklist (CBCL 6-18).
Description
The CBCL 6-18 generates a T-score for each subscale. According to normative data, a T-score above 64 was considered to be significant for the 3 broadband scales, whereas for the syndrome scales, the cut-off for clinical significance was 70.
Time Frame
12 months follow up
Title
Significant changes in the total scores of other psychopathological measures as Children's Depression Inventory (CDI).
Description
Raw scores were converted to T-scores. According to normative data, a T-score above 64 was considered clinical significance.
Time Frame
12 months follow up
Title
Significant changes in the total scores of other psychopathological measures as Multidimensional Anxiety Scale for Children (MASC).
Description
Raw scores were converted to T-scores. According to normative data, a T-score above 64 was considered clinical significance.
Time Frame
12 months follow up
Title
Significant changes in the physiological measures specifically the BMI index
Time Frame
12 months follow up
Title
Number of participants with abnormal laboratory blood test results.
Time Frame
12 months follow up
Title
Significant changes in the endogenous stress response, measured with Cortisol Awakening Response (CAR).
Time Frame
12 months follow up
Title
Significant changes in intra-cortical inhibitory/excitatory motor circuits using paired pulse TMS, measured as short intracortical inhibition and facilitation.
Description
the ratio between MEPs amplitude conditioning stimulus and MEPs amplitude test stimulus alone for each ISI.
Time Frame
6 weeks
Title
Significant changes in sensory-motor integration using paired pulse TMS, measured as SICI/ICF: the ratio between MEPs amplitude (mV) conditioning stimulus (electrical stimulation) and MEP amplitude test stimulus alone for each ISI.
Time Frame
6 weeks
Title
Significant changes in cortical oscillatory patterns (synchronization and desynchronization) in theta, alpha and beta frequencies (Hz) over motor and premotor cortex, using TMS-EEG co-registration.
Time Frame
6 weeks
Title
Significant changes in cortical connectivity using TMS-EEG co-registration combined to report the analysis of the waveform, latency and cortical distribution of TMS-evoked potentials (TEPs) in micronV.
Time Frame
6 weeks
Title
Significant changes in cortical reactivity in terms of TMS-evoked potentials (TEPs) amplitude for time domain (micronV) and frequency bands for spatial domain (Hz), using TMS-EEG co-registration.
Time Frame
6 weeks
Title
Significant changes in Cortical Plasticity evoked by repetitive TMS in terms of different MEP amplitude (mV) recorded at different time-points after repetitive TMS perturbations.
Time Frame
6 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: diagnosis of AN according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition - DSM-5 (American Psychiatric Association & American Psychiatric Association, 2013); condition of under-weight (BMI <18.5 kg/m2); intelligence quotient higher or equal to 85 (IQ ≥ 85); ability to give informed consent under parents' surveillance and guidance Exclusion Criteria: a personal history of neurological/medical/genetic diseases; a personal history of epilepsy; suicide risk; receiving CNS-active drug, other counseling or psychological therapies during the treatment.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Floriana Costanzo
Phone
0668597091
Email
floriana.costanzo@opbg.net
First Name & Middle Initial & Last Name or Official Title & Degree
Valeria Zanna
Email
valeira.zanna@opbg.net
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Floriana Costanzo
Organizational Affiliation
Bambino Gesù Hospital and Research Institute
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Stefano Vicari
Organizational Affiliation
Bambino Gesù Hospital and Research Institute
Official's Role
Study Chair
Facility Information:
Facility Name
Bambino Gesù Hospital and Research Institute
City
Rome
ZIP/Postal Code
00165
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chiara Mennini
Phone
06-68592572
Email
chiara.mennini@opbg.net
First Name & Middle Initial & Last Name & Degree
Rita Alparone
Phone
06-68593580
Email
rita.alparone@opbg.net

12. IPD Sharing Statement

Citations:
PubMed Identifier
21320389
Citation
Brunoni AR, Amadera J, Berbel B, Volz MS, Rizzerio BG, Fregni F. A systematic review on reporting and assessment of adverse effects associated with transcranial direct current stimulation. Int J Neuropsychopharmacol. 2011 Sep;14(8):1133-45. doi: 10.1017/S1461145710001690. Epub 2011 Feb 15.
Results Reference
background
PubMed Identifier
30083095
Citation
Costanzo F, Menghini D, Maritato A, Castiglioni MC, Mereu A, Varuzza C, Zanna V, Vicari S. New Treatment Perspectives in Adolescents With Anorexia Nervosa: The Efficacy of Non-invasive Brain-Directed Treatment. Front Behav Neurosci. 2018 Jul 20;12:133. doi: 10.3389/fnbeh.2018.00133. eCollection 2018.
Results Reference
result

Learn more about this trial

New Treatment Perspectives in Adolescents With Anorexia Nervosa: the Efficacy of Non-invasive Brain-directed Treatment

We'll reach out to this number within 24 hrs